Abstract:Background: Clear cell renal cell carcinoma (ccRCC) remains one of the most lethal urological malignancies even though a great number of improvements in diagnosis and management have achieved over the past few decades. Accumulated evidence revealed that histone deacetylases (HDACs) play vital role in cell proliferation, differentiation and apoptosis. Nevertheless, the biological functions of histone deacetylation modification related genes in ccRCC remains poorly understood. Method: Bulk transcriptomic data and clinical information of ccRCC patients were obtained from the TCGA database and collected from the Chinese PLA General Hospital. A total of 36 histone deacetylation genes were selected and studied in our research. Univariate cox regression analysis, least absolute shrinkage and selection operator (LASSO) regression, random forest (RF) analysis, and protein-protein interaction (PPI) network analysis were applied to identify key genes affecting the prognosis of ccRCC. The 'oncoPredict' algorithm was utilized for drug-sensitive analysis. Gene Set Enrichment Analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was used to explore the potential biological function. The ssGSEA algorithm was used for tumor immune microenvironment analysis. The expression levels of HDAC10 were validated by RT-PCR and immunohistochemistry (IHC). 5-ethynyl-2'-deoxyuridine (EdU assay), CCK-8 assay, cell transwell migration and invasion assay and colony formation assay were performed to detect the proliferation and invasion ability of ccRCC cells. A nomogram incorporating HDAC10 and clinicopathological characteristics was established to predict the prognosis of ccRCC patients. Result: Two machine learning algorithms and PPI analysis identified four histone deacetylation genes that have a significant association with the prognosis of ccRCC, with HDAC10 being the key gene among them. HDAC10 is highly expressed in ccRCC and its high expression is associated with poor prognosis for ccRCC patients. Pathway enrichment and the experiments of EdU staining, CCK-8 assay, cell transwell migration and invasion assay and colony formation assay demonstrated that HDAC10 mediated the proliferation and metastasis of ccRCC cells and involved in reshaping the tumor microenvironment (TME) of ccRCC. A clinically reliable prognostic predictive model was established by incorporating HDAC10 and other clinicopathological characteristics ( https://nomogramhdac10.shinyapps.io/HDAC10_Nomogram/ ). Conclusion: Our study found the increased expression of HDAC10 was closely associated with poor prognosis of ccRCC patients. HDAC10 showed a pro-tumorigenic effect on ccRCC and promote the proliferation and metastasis of ccRCC, which may provide new light on targeted therapy for ccRCC.

KDELR2 Promotes Breast Cancer Proliferation Via HDAC3‐mediated Cell Cycle Progression

HDAC Inhibitors Augmented Cell Migration and Metastasis Through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy

KDELR2 Promotes Glioblastoma Tumorigenesis Targeted by HIF1a Via Mtor Signaling Pathway

HDAC8-dependent Deacetylation of PKM2 Directs Nuclear Localization and Glycolysis to Promote Proliferation in Hepatocellular Carcinoma.

CDKL3 is a Targetable Regulator of Cell Cycle Progression in Cancers

HDAC2 Regulates Cell Proliferation, Cell Cycle Progression and Cell Apoptosis in Esophageal Squamous Cell Carcinoma EC9706 Cells

A Novel Histone Deacetylase Pathway Regulates Mitosis by Modulating Aurora B Kinase Activity.

Endocrine Resistant Breast Cancer Cells with Loss of ERα Expression Retain Proliferative Ability by Reducing Caspase7-Mediated HDAC3 Cleavage

Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells

Class I Histone Deacetylase Inhibition is Synthetic Lethal with BRCA1 Deficiency in Breast Cancer Cells

HDAC3 Deficiency Promotes Liver Cancer Through a Defect in H3K9ac/H3K9me3 Transition

Histone Deacetylase 2 Regulates Doxorubicin (dox) Sensitivity of Colorectal Cancer Cells by Targeting Abcb1 Transcription

HDAC2 promotes the EMT of colorectal cancer cells and via the modular scaffold function of ENSG00000274093.1

Oncogenic Functions of Protein Kinase D2 and D3 in Regulating Multiple Cancer-Related Pathways in Breast Cancer

HDAC5, a Potential Therapeutic Target and Prognostic Biomarker, Promotes Proliferation, Invasion and Migration in Human Breast Cancer

Identification of HDAC10 as a candidate oncogene in clear cell renal carcinoma that facilitates tumor proliferation and metastasis

HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells

DNASE1L3 inhibits hepatocellular carcinoma by delaying cell cycle progression through CDK2

Pharmacological or Transcriptional Inhibition of Both HDAC1 and 2 Leads to Cell Cycle Blockage and Apoptosis Via P21waf1/cip1 and P19ink4d Upregulation in Hepatocellular Carcinoma.

HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness

CHD1L Promotes Cell Cycle Progression and Cell Motility by Up-Regulating MDM2 in Breast Cancer.